logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults.

    Article - En anglais

    Healthy adults =50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (bêta197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 mug each of capsular oligosaccharides from serotypes 6B, 14,18C, 19F, and 23F or with licensed (23-valent, 25 mug/serotype) pneumococcal polysaccharide vaccine (PV).

    Adverse reactions, predominantly local in nature, occurred in 20 of 23 CV recipients versus 13 of 23 PV recipients (P<. 05).

    Compared with mean postvaccination antibody concentrations in PV recipients, those induced by CV were not significantly different for serotypes 6B, 14,18C, and 23F and were lower for 19F (P<. 05).

    Six months later, reimmunization with PV of subjects who had initially received CV elicited a slight boost in antibody concentrations to levels that were not significantly higher than those achieved after the primary vaccination or than those in persons given a single dose of PV.

    Pneumococcal vaccines containing protein-conjugated oligosaccharides may offer no advantage over currently licensed preparations containing unconjugated polysaccharides for immunization of healthy older adults.

    Mots-clés Pascal : Streptococcus pneumoniae, Streptococcaceae, Micrococcales, Bactérie, Vaccination, Toxicité, Réponse immune, Efficacité, Immunoprophylaxie, Immunogénicité, Vaccin, Prévention, Adulte, Homme

    Mots-clés Pascal anglais : Streptococcus pneumoniae, Streptococcaceae, Micrococcales, Bacteria, Vaccination, Toxicity, Immune response, Efficiency, Immunoprophylaxis, Immunogenicity, Vaccine, Prevention, Adult, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0201881

    Code Inist : 002B05B02E. Création : 199608.